SCHEMBL4237226

SCHEMBL4237226

O=c1c2ccccc2nc(-c2cccs2)n1NCc1ccc(C(F)(F)F)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.67
SMN1; SMN2 Q16637 6/20 0.67
ALDH1A1 P00352 5/20 0.67
MAPT P10636 4/20 0.67
HTT P42858 2/20 0.67
HPGD P15428 7/20 0.52
POLB P06746 1/20 0.52
LMNA P02545 6/20 0.51
GAA P10253 3/20 0.49
NPSR1 Q6W5P4 2/20 0.49
RXFP1 Q9HBX9 1/20 0.49
CYP1A2 P05177 2/20 0.49
CYP3A4 P08684 2/20 0.49
CYP2D6 P10635 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
PKM P14618 1/20 0.47
PLA2G1B P04054 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4236261 0.87 KDM4E (0.69) KDM4ESMN1; SMN2ALDH1A1MAPTHTT
SCHEMBL4237693 0.82 SMN1; SMN2 (0.64) KDM4ESMN1; SMN2ALDH1A1MAPTHTT
SCHEMBL4233248 0.82 ALDH1A1 (0.56) KDM4ESMN1; SMN2ALDH1A1MAPTHTT
SCHEMBL4233285 0.81 MAPT (0.55) KDM4ESMN1; SMN2ALDH1A1MAPTHTT
SCHEMBL4233257 0.81 ALDH1A1 (0.53) KDM4ESMN1; SMN2ALDH1A1MAPTHTT
SCHEMBL4233146 0.79 KDM4E (0.52) KDM4ESMN1; SMN2ALDH1A1MAPTHTT
SCHEMBL4241971 0.79 MEN1 (0.55) KDM4ESMN1; SMN2ALDH1A1MAPTHTT
SCHEMBL4233717 0.76 KMT2A (0.61) KDM4ESMN1; SMN2ALDH1A1MAPTHTT
SCHEMBL4242686 0.73 LMNA (0.65) SMN1; SMN2ALDH1A1MAPTHTTHPGD
SCHEMBL4233701 0.73 SMN1; SMN2 (0.63) KDM4ESMN1; SMN2ALDH1A1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 GRK5, PLAAT5, GPBAR1 KDM4E 3161/4885SMN1; SMN2 4767/4885ALDH1A1 3192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.